BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 2757751)

  • 21. 2-Phenylindoles. Effect of N-benzylation on estrogen receptor affinity, estrogenic properties, and mammary tumor inhibiting activity.
    von Angerer E; Strohmeier J
    J Med Chem; 1987 Jan; 30(1):131-6. PubMed ID: 3806590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis of 17beta-estradiol-linked platinum(II) complexes and their cytocidal activity on estrogen-dependent and -independent breast tumor cells.
    Perron V; Rabouin D; Asselin E; Parent S; C-Gaudreault R; Bérubé G
    Bioorg Chem; 2005 Feb; 33(1):1-15. PubMed ID: 15668178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The inhibitory effect of 5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole (D 16726) on estrogen-dependent mammary tumors.
    von Angerer E; Prekajac J; Berger M
    Eur J Cancer Clin Oncol; 1985 Apr; 21(4):531-7. PubMed ID: 3924626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer.
    Bagatell R; Khan O; Paine-Murrieta G; Taylor CW; Akinaga S; Whitesell L
    Clin Cancer Res; 2001 Jul; 7(7):2076-84. PubMed ID: 11448926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
    Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
    Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model.
    Yue W; Wang J; Savinov A; Brodie A
    Cancer Res; 1995 Jul; 55(14):3073-7. PubMed ID: 7606729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.
    Schneider MR; Michna H; Nishino Y; Neef G; el Etreby MF
    Anticancer Res; 1990; 10(3):683-7. PubMed ID: 2369083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidermal growth factor receptors in human breast carcinoma cells: a potential selective target for transforming growth factor alpha-Pseudomonas exotoxin 40 fusion protein.
    Arteaga CL; Hurd SD; Dugger TC; Winnier AR; Robertson JB
    Cancer Res; 1994 Sep; 54(17):4703-9. PubMed ID: 8062268
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl) ethylenediamine]dichloroplatinum(II), a compound with a specific activity on hormone-sensitive breast cancers--evidence for a diethylstilbestrol-like mode of action.
    Schlemmer R; Spruss T; Bernhardt G; Schönenberger H
    Arch Pharm (Weinheim); 1999 Feb; 332(2):59-69. PubMed ID: 10191716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.
    Gust R; Faderl M; Schönenberger H
    J Cancer Res Clin Oncol; 2000 Nov; 126(11):647-54. PubMed ID: 11079729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [N-ethyl- and [N,N'-diethyl-1,2-bis(2,6-difluoro-3-hydroxyphenyl)-ethylenediamine]dichloroplatinum(II): structure and cytotoxic/estrogenic activity in breast cancer cells.
    Gust R; Niebler K; Schönenberger H
    J Med Chem; 2005 Nov; 48(23):7132-44. PubMed ID: 16279771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cisplatinum and transplatinum complexes with benzyliminoether ligands; synthesis, characterization, structure-activity relationships, and in vitro and in vivo antitumor efficacy.
    Sbovata SM; Bettio F; Mozzon M; Bertani R; Venzo A; Benetollo F; Michelin RA; Gandin V; Marzano C
    J Med Chem; 2007 Sep; 50(19):4775-84. PubMed ID: 17713897
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of retinoid binding affinity to retinoic acid receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells.
    Dawson MI; Chao WR; Pine P; Jong L; Hobbs PD; Rudd CK; Quick TC; Niles RM; Zhang XK; Lombardo A
    Cancer Res; 1995 Oct; 55(19):4446-51. PubMed ID: 7671258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The prospect for cisplatin analogs from the experimental standpoint].
    Tashiro T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1358-65. PubMed ID: 2543305
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytostatic and cytotoxic action of Z-1, 1-dichloro-2,3-diphenylcyclopropane in three human breast cancer cell lines.
    ter Haar E; Day BW
    Anticancer Res; 1996; 16(3A):1107-15. PubMed ID: 8702221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2-phenylindole-linked nitroimidazoles as potential radiosensitizers for estrogen receptor positive tumors.
    Erber S; von Angerer E
    Arch Pharm (Weinheim); 1990 Sep; 323(9):591-4. PubMed ID: 2288481
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereoisomeric [1,2-bis(3-hydroxyphenyl)ethylenediamine]platinum(II) complexes, Part III: Evaluation of the mammary tumor inhibiting properties.
    Schertl S; Gust R; Müller R; Spruss T; Schönenberger H
    Arch Pharm (Weinheim); 1992 Feb; 325(2):113-8. PubMed ID: 1605715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of pituitary grafts or prolactin administrations on the hormone sensitivity of ovarian hormone-independent mouse mammary MXT tumors.
    Kiss R; de Launoit Y; Danguy A; Paridaens R; Pasteels JL
    Cancer Res; 1989 Jun; 49(11):2945-51. PubMed ID: 2720654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytostatic activity of an estradiol-linked nitrosourea in MXT mammary carcinoma and L 5222 leukemia.
    Zeller WJ; Schreiber J; Petru E; Eisenbrand G
    Arzneimittelforschung; 1989 Dec; 39(12):1577-9. PubMed ID: 2624608
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction of the estrogenic side effects of the mammary tumor-inhibiting drug [1,2-bis(2,6-dichloro-4-hydroxyphenyl)- ethylenediamine]dichloroplatinum(II) by variation of ring substituents.
    Gust R; Karl J; Faderl M; Schönenberger H
    Arch Pharm (Weinheim); 1995 May; 328(5):457-63. PubMed ID: 7611841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.